Himanshu Patel, MD
Cardiovascular Disease · Rome, GANPI 1972523603
Payments from drug & device makers
Across 194 payments — averaging $76.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Novartis$5K
- Boston Scientific$2K
- Johnson & Johnson$376
- Pfizer$306
- Medtronic$301
- plus $2K from 24 others
What the payments were for
- Consulting fees$4,30429%
- Travel & lodging$4,61131%
- Food & beverage$5,83739%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $5,355 |
| Novartis | 20 | $5,251 |
| Boston Scientific | 15 | $1,504 |
| Johnson & Johnson | 23 | $376 |
| Pfizer | 13 | $306 |
| Medtronic | 2 | $301 |
| Biogen | 6 | $241 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $231 |
| Edwards Lifesciences | 1 | $152 |
| Impulse Dynamics (USA) Inc. | 1 | $134 |
| E.r. Squibb & Sons, L.L.C. | 8 | $119 |
| Lexicon Pharmaceuticals, Inc. | 6 | $102 |
| Cvrx, Inc. | 1 | $95 |
| Actelion Pharmaceuticals US, Inc. | 4 | $83 |
| W. L. Gore & Associates, Inc. | 2 | $68 |
| Merck | 4 | $66 |
| Esperion Therapeutics, Inc. | 4 | $53 |
| Nuwellis, Inc. | 3 | $51 |
| Amgen | 3 | $43 |
| Lantheus Medical Imaging, Inc. | 2 | $32 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Abiomed | 1 | $31 |
| AstraZeneca | 2 | $28 |
| Bardy Diagnostics, Inc. | 3 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$2,254
- CARDIOMEMS$1,751
- WATCHMAN Access System$1,111
- ENTRESTO$772
- OPTIMIZER$267
- ENDURANT IIS$158
- SAPIEN 3 Ultra RESILIA$152
- SYNERGY$149
- Avalus$143
- VYNDAQEL$123
How this compares
$14,794 in reported general payments places this provider in the 80th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 620 | $649,259 |
| XareltoRivaroxaban | 317 | $309,250 |
| EntrestoSacubitril/Valsartan | 221 | $253,540 |
| JardianceEmpagliflozin | 201 | $177,671 |
| FarxigaDapagliflozin Propanediol | 175 | $144,832 |
| Repatha SyringeEvolocumab | 15 | $17,961 |
| BrilintaTicagrelor | 29 | $13,579 |
| Repatha SureclickEvolocumab | 15 | $11,944 |
| Praluent PenAlirocumab | 14 | $8,652 |
| Atorvastatin Calcium | 769 | $6,706 |
| Metoprolol Succinate | 556 | $6,364 |
| Torsemide | 360 | $6,274 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,876 |
| ClopidogrelClopidogrel Bisulfate | 546 | $5,750 |
| Potassium Chloride | 353 | $5,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $306 | $649,259620 claims |
| Johnson & JohnsonXarelto | $376 | $309,250317 claims |
| NovartisEntresto | $5,251 | $253,540221 claims |
| Boehringer IngelheimJardiance | $17 | $177,671201 claims |
| AstraZenecaFarxiga, Brilinta | $28 | $158,411204 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Rome
- Hector PiconRome$113K
- Charles JacksonRome$55K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.